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radiographs from the healthy cohort. The level of reproducibility
was assessed using root-mean square coefﬁcients of variation
(RMSCV%).
To determine whether varying anatomic landmark choice affected
precision of KA measurement, tibial and femoral rules were
aligned such that: i) end points of both rules were placed at inner
or outer cortical edges, ii) midpoint to midpoint distance from
centre rule was equal to 10 ± 0.5 cm or 5.0-7.0 ± 0.5 cm and iii)
femoral rule was aligned parallel to femoral condyles or to tibial
plateau. The Bland-Altman analysis method was conducted on
data obtained from varying anatomic landmarks (CI = 95%).
Results: Reproducibility analyses revealed a high degree of
intraobserver (RMSCV = 0.29%) and interobserver (RMSCV =
0.33%) reproducibility. In test-retest (n = 32, RMSCV = 0.86%)
and experience-inexperience (n = 32, RMSCV = 0.61%) exper-
iments, variance was higher than both intra- and interobserver
variances but still well under 1% (Table I). Varying the orienta-
tion of tibial and femoral rules according to anatomic landmarks
did indeed produce a difference that exceeded the a priori limit
of agreement of -1.55° to 1.65° deﬁned for digital and manual
method discrepancy in KA measurement.
Table I. Precision errors in reproducibility analyses of KA measurement
Reproducibility Absolute mean difference RMSSD RMSCV
comparisons (°) (°) (%)
Intraobserver 0.56 0.51 0.29
Interobserver 0.66 0.59 0.33
Experience-Inexperience 1.03 1.10 0.61
Test-Retest 1.65 1.55 0.86
Conclusions:Our custom designed software allowed for efﬁcient
and rapid measurement of KA in digitized knee radiographs of OA
patients. Although test-retest analyses were only performed in a
healthy cohort, we anticipate a similar degree of reproducibility in
an OA sample, thus allowing assessment of knee OA progression
in the clinical research setting. Nevertheless, readers should still
be cautious as to employing a standardized set of anatomic
landmarks during measurement since the arbitrary selection of
landmarks may result in imprecise KA measurement even with
digital techniques.
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Purpose: Osteoarthritis (OA) is the most common diagnosis
made in older patients with knee or hip pain in primary care.
The prevalence of many other disabling conditions also rises
with age, and some chronic conditions can be found together
with OA. An important question is whether comorbidity impairs
the health of patients with OA. CHECK (Cohort Hip and Cohort
Knee)is a prospective multicentre 10- year follow-up study on the
onset and progression of OA in participants with early complaints
of hip or knee, using the ICF model as a conceptual framework.
Objective: to investigate whether the number of comorbidities
is associated with the complaints of participants with early os-
teoarthritis.
Methods: A participant is included if he has complaints (pain
and/or stiffness) of knee and/or hip, is aged 45- 65 years, has
never or not longer than 6 months ago visited the general
practitioner for these complaints. The collected variables are
categorized according to the dimensions of the ICF model. Body
functions and structure are measured with the WOMAC (also
the limitations in activities), physical examination, standardized
radiography of knees and hips and by collecting blood and urine.
The inﬂuence of the environmental and personal factors are
also investigated; the comorbidity (self- reported) and the health
related quality of life (SF-36).
Results: 1002 participants are included in 10 center nationwide
in the Netherlands with a mean age of 56 years. Two hundred
and eighty- seven participants(29%) reported no comorbidity,
305 (30%) reported one comorbidity, 200 (20%)reported two co-
morbidities and 210(21%) at least 3 comorbidities. There was
a signiﬁcant inverse association with the number of comorbidi-
ties and the pain, the stiffness and the function subscale of
the WOMAC. Spearman’s correlation between the number of
comorbidities and the WOMAC were respectively: pain -0,210*,
stiffness -0,218* and function -0,243* (*p<0,001). All dimensions
of the SF-36 also have a signiﬁcant negative correlation with the
number of comorbidites. The strongest association between the
number of comorbidities and an individual SF-36 dimension was
seen for vitality -0,322 (p<0,001).
Conclusions: The CHECK study is a cohort of participants
with complaints of hip or knee. The complaints pain, stiffness
and limitation in activities, measured with the WOMAC disease
speciﬁc questionnaire, were inversely related to the number of
comorbidities. Indicating that participants with more comorbidities
have lower (worse) scores than subjects with fewer comorbidities.
For a more general insight into the participants health, the SF-
36 is used. These results showed an impairment of health
related quality of life which was also negatively associated with
increasing number of comorbidities.
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mus Med.Center, St. Maartensclinic, Med.Spectrum Twente,
Twenteborg Hospital, Academic Hospital Maastricht, Jan van
Breemen Institute/Academic Med. Center Amsterdam/VU Med.
Center, Wilhelmina Hospital Assen, Martini Hospital Gronin-
gen/Paramed. Center for Rheum& Rehab, Kennemer Gasthuis
Haarlem and University Med.Center Utrecht
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Purpose: Many people take vitamin D supplements in order to
prevent vitamin D deﬁciency. However, a number of clinical trials
have suggested that typical supplementary doses of vitamin D
are not adequate to prevent deﬁciency. This study examined the
relationship between vitamin D supplementation and vitamin D
deﬁciency among persons with knee osteoarthritis (OA).
Methods: This cross-sectional study evaluated baseline data
from the ﬁrst hundred patients aged ≥ 49 years participating in
a clinical trial of knee OA. Information collected included demo-
graphic characteristics, daily vitamin D supplement intake, weight
and height and month of blood draw. Serum 25(OH)D level was
measured using liquid chromatography/tandem mass spectrom-
etry. Vitamin D deﬁciency was deﬁned by serum 25(OH)D <
30 ng/ml. Multivariate logistic regression models were used to
identify factors associated with vitamin D supplement intake and
vitamin D deﬁciency. Gender, age, race, education, and BMI
were included in all analyses.
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Results: The study included 65 women and 35 men, with 77%
being White, 18% African American, 2% Asian, and 3% Other.
Mean age of the subjects was 63.5 years (± 8.7). 54% of the
subjects reported daily vitamin D supplementation, with 31%
taking <400 IU vitamin D and 23% taking ≥400 IU. Mean base-
line serum (OH)D level was 31.6 (± 12.6) ng/ml, with 47% of
subjects found to be vitamin D deﬁcient. Many subjects were
vitamin D deﬁcient in spite of supplementation (42% who took
≤400 IU vitamin D, and 30% of those taking >400 IU vitamin
D). However, after adjustment for age, gender, race, BMI, edu-
cation, and month of blood draw, vitamin D supplementation was
associated with decreased risk of vitamin D deﬁciency (subjects
taking 1-400 IU vitamin D vs. no-taking, OR = 0.51, 95% CI,
0.16-1.63; subjects taking >400 IU vitamin D vs. no-taking, OR
= 0.26, 95% CI, 0.07-1.04), p trend = 0.047. In these models,
lower vitamin D levels were inversely associated with education
(college graduate or above vs. under, OR = 0.28, 95% CI, 0.09-
0.84), and positively associated with African-American race (OR
= 4.10, 95% CI, 0.94-18.0).
Conclusions: Many individuals with knee OA are vitamin D
deﬁcient in spite of daily vitamin D supplementation. Current
recommendation with respect to vitamin D supplementation may
require reconsideration for individuals with OA.
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Purpose: Hip osteoarthritis (OA) is a debilitating musculoskeletal
disorder, characterized by chronic pain, affecting health related
quality of life. Lumiracoxib is a selective COX-2 inhibitor that
provides an alternative to traditional NSAIDs for the treatment of
OA. The present study was designed to demonstrate the efﬁcacy
and safety of lumiracoxib (100 mg od) compared with placebo in
patients with primary hip OA. Celecoxib (200 mg od) was used
as the positive control.
Methods: The primary efﬁcacy variables included patient’s global
assessment of disease activity (0-100 mm VAS), WOMAC™ 3.1
LK pain sub-scale score and WOMAC™ difﬁculty performing
daily activities (DPDA) sub-scale score (at Week 13). Prespec-
iﬁed secondary efﬁcacy variables included response to treat-
ment according to Osteoarthritis Research Society International
(OARSI) criteria at Weeks 4, 8 and 13; and minimal clinically im-
portant improvement (MCII) for hip OA pain by visit. The efﬁcacy
in the subgroup of patients ≥65 years was also prespeciﬁed to
be analyzed for these primary outcomes.
Results: A total of 1262 primary hip OA patients aged ≥40
years (490 were ≥65 years of age) were randomized to receive
lumiracoxib 100 mg od (n=427), celecoxib 200 mg od (n=419),
or placebo (n=416) over a period of 13 weeks. Lumiracoxib was
signiﬁcantly superior to placebo in all primary efﬁcacy variables
and provided similar pain relief compared with celecoxib at 13
weeks (in both overall population and ≥65 years sub group, Table
1). The treatment response in <65 age group was also similar
to the overall population and statistically signiﬁcant compared to
placebo.
Table 1. Efﬁcacy of lumiracoxib versus placebo for primary outcomes (estimated
difference after 13 weeks)
Lumiracoxib vs Placebo
LSM difference (95% CI)
Overall Population ≥65 years
Patient’s global assessment of
disease activity (VAS, mm) -8.59 (-11.84, -5.33)* -9.60 (-14.94, -4.25)*
WOMAC™ pain (0-20) scores -1.12 (-1.63, -0.60)* -1.63 (-2.48, -0.78)*
WOMAC™ DPDA (0-68) scores -3.58 (-5.24, -1.91)* -4.16 (-6.90, -1.42)**
*p<0.001, **p=0.003.
Similar results for all primary endpoints were observed for cele-
coxib vs placebo in the overall population and patients ≥65 years.
A greater proportion of patients in the lumiracoxib group (63.0%,
67.0%, 65.8%) had a treatment response according to OARSI
criteria at Weeks 4, 8 and 13 compared with placebo (45.4%,
50.0%, 53.6%) and the response was similar to that in the cele-
coxib group (63.7%, 67.5%, 67.8%). Lumiracoxib and celecoxib
were statistically superior to placebo in the achievement of MCII
for target hip OA pain after 4 weeks (p≤0.001; p=0.004), 8 weeks
(both p≤0.001), and 13 weeks (both p≤0.001) of treatment. The
incidence of adverse events in the lumiracoxib, celecoxib and
placebo groups was 56.4%, 53% and 47.6%, respectively. The
overall percentage of serious adverse events (SAEs) was 1.9%,
1.0% and 2.2% in the respective groups. There were no fatal
SAEs in the lumiracoxib and placebo groups. Two deaths oc-
curred in the celecoxib group that were not suspected to be
study drug related. Two patients (0.5%) had AST and/or ALT
elevations >3 x ULN in the placebo group versus no elevations
in the active treatment groups.
Conclusions: Lumiracoxib 100 mg od and celecoxib 200 mg od
were well tolerated and provided similar pain relief and improve-
ment in functional status in patients with primary hip OA. Efﬁcacy
was maintained in patients ≥65 years.
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Purpose: The placebo effect is inherent to all treatments. Phar-
macotherapy trials assess whether speciﬁc effects of an agent
are signiﬁcantly greater than non-speciﬁc inﬂuences (placebo) on
treatment outcomes. In OA trials, rates of placebo response often
approach or exceed 50%. Despite this, very little is known about
sociodemographic or clinical predictors of placebo response.
Methods: Data were drawn from placebo arm of North Amer-
ican patients in a large clinical trial designed to evaluate the
clinical effects of risedronate on knee OA (KOSTAR). OARSI
pain criteria (20% and 50% decrease in WOMAC pain) were
used to classify participants at 6 months as placebo respon-
ders. We examined whether placebo response was associated
with baseline demographic, clinical, and radiographic parameters
including: age, gender, race, BMI, work status, WOMAC (pain,
stiffness, function), patient global assessment, OA at other sites,
NSAID, analgesic and glucosamine use, joint space width (JSW)
and osteophyte grade.
Results: Of 311 OA patients who started the trial, 269 (86%)
completed the 6 month evaluations. Subjects were mostly female
(60%) and white (84%) with a mean (± SD) age of 60.4 ±
8.9, BMI of 30.2 ± 5.0, OARSI osteophyte grade of 1.6 ±
0.6 and baseline pain (WOMAC) of 35.1 ± 21.5. Nearly half
(49%) reported a 20% decrease in pain while 29% reported a
50% decrease, with no between-group differences by gender or
